Breast Cancer from a Public Health Perspective

Breast Journal

Volumn 10, Issue 2, 2004, Pages 136-140

  Love, Richard R ^a,d   Love, Susan M ^b   Laudico, Adriano V ^c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PHILIPPINE GENERAL HOSPITAL   (Philippines)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Public health

Indexed keywords

ADJUVANT THERAPY; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; HEALTH SERVICE; HIGH RISK POPULATION; MAMMOGRAPHY; PUBLIC HEALTH; REVIEW;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DEVELOPING COUNTRIES; FEMALE; HUMANS; MAMMOGRAPHY; MEDICALLY UNDERSERVED AREA; PUBLIC HEALTH; WOMEN'S HEALTH; WORLD HEALTH;

EID: 1642273148     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.21375.x     Document Type: Review

References (40)

1. Parkin DM. The world cancer burden into the 21st century. Presented at the 16th Asia Pacific Cancer Conference, Manila, Philippines, November 21, 2001.
2. Phillips KA, Glendon G, Knight JA. Putting the risk of breast cancer in perspective. N Engl J Med 1999;340:141-44.
3. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
5. Love RR. Chemoprevention with tamoxifen: known benefits and toxicities. In: Tobias JS, Houghton J, Henderson IC, eds. Breast Cancer: New Horizons in Research and Treatment. London: Arnold, 2001:152.
6. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
7. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
8. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-97.
9. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast dancer primary prevention. Ann Surg Oncol 2001;8:580-85.
10. Vogel VG, Costantino JP, Wickerham DL, Cronin WM. Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2002;94:1504.
11. Gotzsche PD, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34.
12. Retsky M, Demicheli R, Hrushesky W. Breast cancer screening for women aged 40-49 years: screening may not be the benign process usually thought [letter]. J Natl Cancer Inst 2001;93:1572.
13. Brownlee S. Search and destroy: why mammograms are not the answer. New Republic 2002; April 22:24.
14. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-77.
15. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 2001;93:1624-32.
16. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.
17. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N EnglJ Med 1997;337:956-62.
18. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000;355:1757-70.
19. Marks LB, Hardenbergh P, Prosnitz LR. Mounting evidence for postmastectomy locoregional radiation therapy. Oncology 1999;13:1123-35; discussion 35-42, 1144.
20. Marks LB, Hardenbergh PH, Winer ET, Prosnitz LR. Assessing the cost-effectiveness of postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999;44:91-98.
21. Dunscombe P, Samant R, Roberts G. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients. Int J Radial Oncol Biol Phys 2000;48:977-82.
22. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991;324:160-68.
23. Ejlertsen B, Dombernowsky P, Mouridsen HT, et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP) [abstract 248]. Proc Annu Meet Am Soc Clin Oncol 1999;18:66a.
24. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Association study. J Clin Oncol 2002;20:4628-35.
25. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20:4621-27.
26. Roché HH, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients with positive hormone-receptor and 1-3 node-positive tumor: results of the FASG 06 trial [abstract 279]. Proc Annu Meet Am Soc Clin Oncol 2000;19:72a.
27. Pritchard KI. Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift? [editorial]. J Clin Oncol 2002;20:4611-14.
28. Love RR, Duc NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. [This article has also been published in Vietnamese as Duc NB, Dinh NV, Love RR. Adjuvant oophorectomy and tamoxifen in treatment of Vietnamese and Chinese pre-menopausal operable breast cancer cases. J Pract Med 2002;431:200-208.] J Clin Oncol 2002;20:2559-66.
29. Love RR, Duc NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. [This article has also been published in Vietnamese as Duc NB, Dinh NV, Love RR. Adjuvant oophorectomy and tamoxifen in treatment of Vietnamese and Chinese pre-menopausal operable breast cancer cases. J Pract Med 2002;431:200-208.] J Clin Oncol 2002;20:2559-66.
30. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol 2001;19:3817-27.
31. Love RR, Duc NB, Dinh NV, etal. Mastectomy and oophorectomy by menstrual cycle phase in operable breast cancer. J Natl Cancer Inst 2002;94:662-69.
32. Davidson NE, Levine M. Breast cancer consensus meetings: vive la difference? J Clin Oncol 2002;20:1719-20.
33. Love RR. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer [letter]. J Clin Oncol 2002;20:879-80.
34. Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000;26:151-68.
35. Modi S, Panageas KS, Duck ET, et al. Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 2002;20:3665-73.
36. Matsuda MLD, Laudico AV, Cabaluna ND, et al. Evidence-based clinical practice guidelines on the diagnosis and management of breast cancer. Part II. Locally advanced breast cancer, locally recurrent breast cancer, and metastatic breast cancer. Philippine J Surg Spec 2001;56:135-64.
37. World Health Organization. Cancer Pain Relief with a Guide to Opioids Availability, 2nd ed. Geneva, Switzerland: WHO, 1996.
38. World Health Organization. National Cancer Control Programme: Policies and Management Guidelines. Geneva, Switzerland: WHO, 1995.
39. World Health Organization. Achieving Balance in National Opioids Control Policy: Guidelines for Assessment. Geneva, Switzerland: WHO, 2000.
40. United Nations Economic and Social Council. Committee on Economic and Cultural Rights. General Comment No. 14: the Right to the Highest Attainable Standard of Health. New York: United Nations, 2000.